Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-directed RNA polymerase III subunit C (POLR3C)
- Target
- POLR3C
- Molecular classification
- Enzyme, RNA polymerase subunit, Component of transcription machinery
01
Overview
DNA-directed RNA polymerase III subunit C (POLR3C) is a core protein component of the eukaryotic RNA polymerase III complex, which is responsible for the transcription of small, essential RNAs (such as tRNAs and 5S rRNA) vital to cellular protein synthesis and some aspects of innate immunity. POLR3C plays a central structural and functional role in transcription initiation and elongation, forming part of the polymerase core. Mutations or dysregulation of POLR3C and other Pol III subunits are linked to various human diseases, including neurodevelopmental disorders and altered cancer cell phenotype through effects on cellular growth, division, and antiviral response.
- Other names
- POLR3CRPC3 (commonly in yeast)RNA polymerase III subunit C
02
Mechanism of action
Not specifically defined for POLR3C, but inhibitors of Pol III function by blocking transcription of Pol III-dependent genes, impacting cellular growth and proliferation.
03
Biological functions
Transcription of small RNAs (tRNA, 5S rRNA, other small, untranslated RNAs)Essential for transcription initiation and elongation by RNA polymerase III
04
Disease associations
Cancer (upregulation of Pol III activity noted in tumors)Neurodevelopmental disorders (certain mutations linked to human disease)Infection/Innate immunity (mutations may impair cytosolic DNA sensing)
05
Safety considerations
Inhibition or mutation can impair fundamental transcription of essential small RNAs, leading to toxicity in normal cellsMutations associated with neurodevelopmental defects and risk of viral infections (due to impaired DNA sensing)
06
Interacting drugs
None in routine clinical use or advanced development specifically targeting POLR3C; research into global Pol III inhibition (e.g., by ML-60218, a Pol III inhibitor)
07
Biomarkers
No specific biomarkers in routine clinical practice for POLR3C specifically; upregulation of Pol III activity generally may be used in some preclinical studies
Beyond the preview
Go deeper on DNA-directed RNA polymerase III subunit C (POLR3C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA-directed RNA polymerase III subunit C (POLR3C).